---
id: 139
title: Hepatitis B Virus (HBV) Treatment and Management
category: organisms
subcategory: viruses
tags: [HBV, hepatitis-B, tenofovir, entecavir, HBeAg, cirrhosis]
difficulty: medium
---

## Question

When and how is chronic HBV treated? Use the **"Tenofovir or Entecavir (First-Line), Treat if Active Disease or Cirrhosis"** framework.

## Answer

### **Chronic Hepatitis B Definition:**
- **HBsAg positive ≥6 months**
- **Detectable HBV DNA**

### **Treatment Indications:**

**Definite Treatment:**
- **HBeAg-positive chronic hepatitis:** HBV DNA >20,000 IU/mL + ALT >2× ULN (or >ULN if liver biopsy shows inflammation/fibrosis)
- **HBeAg-negative chronic hepatitis:** HBV DNA >2,000 IU/mL + ALT >2× ULN (or >ULN if inflammation/fibrosis)
- **Compensated cirrhosis:** Any detectable HBV DNA (regardless of ALT)
- **Decompensated cirrhosis:** Any detectable HBV DNA (urgent treatment)

**Consider Treatment:**
- **Age >40 years:** HBV DNA >2,000 IU/mL + ALT persistently normal + family history of HCC or significant fibrosis on biopsy
- **Extrahepatic manifestations:** PAN, membranous GN
- **Immunosuppressive therapy:** Any detectable HBV DNA (prevent reactivation)

**Monitor Without Treatment (Inactive Carrier):**
- **HBeAg negative**, **anti-HBe positive**
- **HBV DNA <2,000 IU/mL**
- **ALT persistently normal**
- **No cirrhosis**

### **First-Line Treatment:**

| Drug | Dosing | Advantages | Disadvantages |
|------|--------|-----------|---------------|
| **Tenofovir alafenamide (TAF)** | **25mg PO daily** | **Preferred**, high barrier to resistance, **less renal/bone toxicity** than TDF | More expensive |
| **Tenofovir disoproxil fumarate (TDF)** | **300mg PO daily** | High barrier to resistance, extensive data | **Renal toxicity**, bone loss |
| **Entecavir** | **0.5mg PO daily** (1mg if lamivudine-resistant) | High barrier to resistance, well-tolerated | Less effective if prior lamivudine resistance |

**Duration:**
- **Typically lifelong** (especially if cirrhosis)
- **Can consider stopping** if HBeAg seroconversion achieved + sustained virologic suppression + no cirrhosis (controversial, high relapse rate)

### **Goals of Therapy:**

**Primary:**
- **Virologic suppression:** HBV DNA undetectable (<10-20 IU/mL)
- **Biochemical response:** ALT normalization
- **Prevent cirrhosis progression**, **prevent HCC**

**Secondary (Desirable but Uncommon):**
- **HBeAg seroconversion** (HBeAg loss + anti-HBe gain) - achievable in ~20-30%
- **HBsAg loss** (functional cure) - rare (<10% after many years), but goal

### **Monitoring:**

**On Treatment:**
- **Every 3-6 months:** HBV DNA, ALT, HBeAg/anti-HBe (if initially HBeAg+)
- **Every 6-12 months:** HCC surveillance (ultrasound ± AFP) if cirrhosis or high-risk
- **Renal function** (if on TDF - CrCl, phosphate, urinalysis)
- **Bone density** (if on TDF + risk factors)

**Treatment Response:**
- **Complete response:** HBV DNA undetectable + ALT normal
- **Partial response:** HBV DNA decline but detectable + ALT may be elevated
- **No response:** <1 log decline in HBV DNA at 12 weeks → consider resistance testing, switch therapy

## Key Points

### **HBV Reactivation:**

**Risk Factors:**
- **Immunosuppressive therapy:** Rituximab (highest risk), chemotherapy, TNF-α inhibitors, corticosteroids (≥20mg prednisone × ≥4 weeks)
- **HBsAg positive** OR **isolated anti-HBc positive** (occult HBV)

**Prevention:**
- **Screen all patients** before immunosuppression (HBsAg, anti-HBc, anti-HBs)
- **If HBsAg+:** Start **tenofovir or entecavir** before immunosuppression, continue during + ≥6-12 months after
- **If anti-HBc+ (HBsAg-):** Monitor HBV DNA monthly OR preemptive therapy (especially if rituximab)

**Flare:**
- **ALT >5-10× ULN**, jaundice, coagulopathy
- Can be **fatal** (especially if cirrhosis)

### **Resistance:**

**Low Barrier to Resistance:**
- **Lamivudine, telbivudine, adefovir** - avoid as monotherapy (high resistance rates)

**High Barrier to Resistance:**
- **Tenofovir (TAF/TDF), entecavir** - resistance rare (<1% over many years)

### **HBV and Pregnancy:**

**Management:**
- **Tenofovir (TDF or TAF)** safe in pregnancy (category B)
- **High viral load (>200,000 IU/mL):** Start tenofovir in **3rd trimester** (week 28-32) to prevent perinatal transmission
- **Neonatal prophylaxis:** HBIG + HBV vaccine within 12 hours of birth (prevents 85-95% of transmission)

### **HCC Surveillance:**
- **Ultrasound ± AFP every 6 months** if:
  - Cirrhosis (any etiology)
  - Non-cirrhotic HBV with high-risk: Age >40, family history of HCC, Asian male >40, Asian female >50, African >20

### **Clinical Pearls:**
- **Tenofovir (TAF preferred) or entecavir** = first-line
- **Treat if:** HBV DNA elevated + ALT elevated OR cirrhosis with any detectable HBV DNA
- **High barrier to resistance:** Tenofovir, entecavir (resistance <1%)
- **Screen before immunosuppression:** Prevent HBV reactivation (can be fatal)
- **HCC surveillance:** Ultrasound ± AFP every 6 months (if cirrhosis or high-risk)
- **Pregnancy:** Tenofovir safe, start if viral load >200,000 IU/mL (3rd trimester)

## Sources

- [AASLD: Hepatitis B Guidelines 2024]
- [EASL: HBV Management 2024]

## Media

N/A
